How it works
Amylin is a hormone co-released with insulin that promotes fullness and slows gastric emptying — a separate satiety pathway from GLP-1. Pairing an amylin analogue with a GLP-1 drug is the rationale for combining two appetite mechanisms.
The evidence
Phase 3 data for CagriSema is emerging; results have been mixed relative to sky-high expectations but still show substantial weight loss. As an investigational combination, treat any figure as provisional and read the research guide.
Safety
Side effects reported so far track the incretin class — largely gastrointestinal. Long-term human safety of amylin analogues in this context is still being established in trials.
FAQ
The investigational combination of cagrilintide + semaglutide, pairing amylin and GLP-1 mechanisms.
No — investigational, in Phase 3 at time of writing.
Sources
This profile summarizes the following. Follow the links to read the originals — and remember that summaries age, so check for newer information.
- Retatrutide/cagrilintide/survodutide status overview
- GLP-1 agonists for obesity: outcomes & risks (PMC)
Inclusion here is not endorsement of any source's claims; several are cited so you can compare how different outlets characterize the same evidence.
Reviewed by Theo — part of the PepConnection crew.